InvestorsHub Logo
Followers 12
Posts 866
Boards Moderated 0
Alias Born 06/20/2013

Re: None

Wednesday, 04/12/2017 10:22:32 AM

Wednesday, April 12, 2017 10:22:32 AM

Post# of 628
Luminar Media Group, Inc., (Luminar, OTCMKTS: LRGR), reports that the development of the working prototype for the patent pending TherOZap(TM) is scheduled for completion prior to the end of March 2017. A selection of features and optimal components have been finalized for the working prototype. As previously reported Jenex expects to test the working prototype to determine its effectiveness at inactivating both the Zika and West Nile virus and potentially other mosquito borne diseases. Testing will be initiated by a world renowned scientific research lab upon completion of the working prototype.

Luminar CEO, Chris Cook commented;

"As we approach the home stretch of product development, Luminar is looking forward to the next stage of the product development where we can focus on sales and marketing strategies."

Rob Fia, Jenex CEO commented:

"We are pleased to have advanced the design process further with our TherOZap(TM) device and excited to finalize the working prototype."

Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.

About Jenex

Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (NEX:JEN.H). For more information visit: www.thejenexcorporation.com or www.therozap.com